Glenmark’s Q1 FY 2021-22 Results
Glenmark’s MDA Q1 FY 2021 – 22
Glenmark Pharma reports revenue growth of 26% and PAT growth of 21% YoY for Q1 FY 2021-22
Glenmark’s Q4 FY 2020-21 Results
Glenmark’s MDA Q4 FY 2020 – 21
Glenmark’s consolidated revenues grow 2.8% to Rs. 1,09,439 Mn in FY21
Know More
Glenmark Pharma reports revenue growth of 26% and PAT growth of 21% YoY for Q1 FY 2021-22
Know MoreGlenmark is a leading, research–based global pharmaceutical company
Know More
X
This website uses cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details refer to our Terms of Use Policy.